

**UPLOAD OF INFORMATION ON ICSR WEBSITE FOR PATENT APPLICATIONS NOT YET PUBLISHED BY IPO**

|  |  |
| --- | --- |
| **IITM REF NO.** | 1200 |
| **TITLE** | Cancer chemopreventive formulation of PM 002/Broad spectrum anticancer formulation of PM 002 |
| **FILING DATE** | 17/11/2014 |
| **STATUS** | Not yet published |
| **DEPARTMENT** | Biotechnology |
| **INVEN** | Dr.Rama S Verma |
| **EMAIL ID** | vermars@iitm.ac.in |
| **ABSTRACT** | **Cancer is disease that is characterized by abnormal proliferation and growth of malignant cells, which can then invade adjoining parts of the body and spread to other organs and a major cause of death. Cancer Chemotherapy is use of drugs to inhibit or kill proliferating cancer celIs. The present invention deals with anticancer activity of herbal extract that is mainly involved in causing cell death (apoptosis) in solid and leukemic cancer cells while normal cells remain unaffected. Agents that can trigger the process of apoptosis at low doses in cancer cells are therefore considered potentially important for the development of anti­ cancer chemotherapeutics.** |

|  |  |
| --- | --- |
| **IITM REF NO.** | 1199 |
| **TITLE** | Synergistic herbal formulation for treatment of cancer |
| **FILING DATE** | 24/10/2014 |
| **STATUS** | Not yet published |
| **DEPARTMENT** | Biotechnology |
| **FACULTY** | Dr.Rama S Verma |
| **EMAIL ID** | vermars@iitm.ac.in |
| **ABSTRACT** | **Skin cancer is the most common cancer in Caucasian populations caused by exposure to UV rays and harmful chemicals. Melanoma and Non melanoma are two types of skin cancers. Chronic sun exposure is also associated with Squamaous Cell Carcin oma a Non melanoma type of cancer. Squamaous Cell Carcinoma is known to cause 2-6% risk of metastasis resulting in mortality. The present invent ion relates to therapeutic applicati ons of a synergistic herbal formulation mainly composed of combination of terpenes for the treatment of human n on melanoma skin cancer. The formulation comprises 2 terpenes which work in synergy, resultin g in apoptotic cell death of skin cancer cells. Synergism between drugs allows reduction of doses and helps to minimise the adverse effect of toxicity on normal cells while maintaining its theraputic effect on cancer cells.** |

**[INVENTOR] [CTEO]**